BR112018072968A2 - peptídeos monolipidados resistentes às proteases - Google Patents

peptídeos monolipidados resistentes às proteases

Info

Publication number
BR112018072968A2
BR112018072968A2 BR112018072968-0A BR112018072968A BR112018072968A2 BR 112018072968 A2 BR112018072968 A2 BR 112018072968A2 BR 112018072968 A BR112018072968 A BR 112018072968A BR 112018072968 A2 BR112018072968 A2 BR 112018072968A2
Authority
BR
Brazil
Prior art keywords
peptides
protease resistant
monolipidated
amino acids
resistant peptides
Prior art date
Application number
BR112018072968-0A
Other languages
English (en)
Inventor
A. Bednarek Maria
Original Assignee
Medimmune Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Limited filed Critical Medimmune Limited
Publication of BR112018072968A2 publication Critical patent/BR112018072968A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção fornece peptídeos resistentes às proteases, métodos para a preparação de tais peptídeos, assim como composições compreendendo peptídeos resistentes às proteases e um método de tratamento utilizando tais peptídeos. determinou-se que uma combinação de lipidação de certos resíduos de aminoácidos e substituição de aminoácidos alternativos por aminoácidos naturais e aminoácidos adicionais adicionados à cadeia peptídica produz peptídeos resistentes às proteases.
BR112018072968-0A 2016-06-09 2017-06-08 peptídeos monolipidados resistentes às proteases BR112018072968A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662347693P 2016-06-09 2016-06-09
US62/347,693 2016-06-09
PCT/EP2017/063905 WO2017211922A2 (en) 2016-06-09 2017-06-08 Protease-resistant mono-lipidated peptides

Publications (1)

Publication Number Publication Date
BR112018072968A2 true BR112018072968A2 (pt) 2019-02-19

Family

ID=59078034

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072968-0A BR112018072968A2 (pt) 2016-06-09 2017-06-08 peptídeos monolipidados resistentes às proteases

Country Status (10)

Country Link
EP (1) EP3468987A2 (pt)
JP (1) JP2019525732A (pt)
KR (1) KR20190017017A (pt)
CN (1) CN109195984A (pt)
AU (1) AU2017277594A1 (pt)
BR (1) BR112018072968A2 (pt)
CA (1) CA3025592A1 (pt)
IL (1) IL263292A (pt)
MX (1) MX2018014966A (pt)
WO (1) WO2017211922A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002977A (es) * 2017-09-22 2020-11-06 Regeneron Pharma Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
EP3774862B1 (en) 2018-04-05 2022-06-08 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
EP4281464A1 (en) 2021-01-20 2023-11-29 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
TW202346323A (zh) * 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057189B1 (en) * 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
JP2017502003A (ja) 2013-12-13 2017-01-19 メディミューン リミテッド プロテアーゼ耐性ペプチド
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽

Also Published As

Publication number Publication date
IL263292A (en) 2018-12-31
EP3468987A2 (en) 2019-04-17
MX2018014966A (es) 2019-08-14
WO2017211922A2 (en) 2017-12-14
AU2017277594A1 (en) 2019-02-07
CA3025592A1 (en) 2017-12-14
KR20190017017A (ko) 2019-02-19
WO2017211922A3 (en) 2018-01-18
CN109195984A (zh) 2019-01-11
JP2019525732A (ja) 2019-09-12

Similar Documents

Publication Publication Date Title
CL2017001883A1 (es) Compuestos antisenescentes y usos de los mismos
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
CR20130667A (es) Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales
NI201600028A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos.
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
CO7461145A2 (es) Péptidos y composiciones para el tratamiento de daño articular
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
BR112018076215A2 (pt) partículas e composições de nicotina
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112016013157A2 (pt) peptídeos resistentes à protease
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
BR112021025432A2 (pt) Composições de proteína anti-vegf e métodos para a produção das mesmas
EA201792362A1 (ru) Композиции и способы для лечения целиакии спру
BR112019005886A2 (pt) tratamento com água de material lipídico
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
CR20180008A (es) Variantes de il-37
NZ744289A (en) Composition containing amino acids
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
BR112017011226A2 (pt) peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
SG11201804902UA (en) A composition for improving memory, learning ability, and cognitive ability

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]